Nature Medicine | Spoonful of Medicine

Better animal models needed for malaria vaccine development, experts say

On Tuesday, highly-anticipated preliminary results from a phase 3 clinical trial of the RTS,S vaccine against malaria found that vaccinated young children had a 56% lower risk of developing the infection. The vaccine’s maker, London’s GlaxoSmithKline (GSK), has been involved with the vaccine since the early 1980s. But its history goes back further to mouse research conducted at New York University (NYU) in the 1960s. Yet, despite a half century of research into malaria vaccines and numerous clinical trials, laboratory models of the disease have changed little — a fact that experts say could be hindering the development of new vaccines. 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.